Clinical trials: Recurrent Gallbladder Carcinoma
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well sorafenib works in treating patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00238212
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and…
- Trial name
- NCT03768375
- Testing
- conventional chemotherapy(FORFIRINOX) combined with target agents, conventional chemotherapy(FORFIRINOX)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003557
- Testing
- dolastatin 10
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
This phase II trial studies how well selumetinib and Akt inhibitor MK-2206 work in treating patients with refractory or advanced gallbladder or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
- Trial name
- NCT01859182
- Testing
- selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00033540
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 112 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00033462
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00658593
- Testing
- capecitabine, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 8 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Biliary Tract Carcinoma, Gallbladder Carcinoma
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
This is a phase II study (the second stage of testing a new drug or new drug combinations) to see how useful two different schedules of study drug selumetinib with cisplatin and gemcitabine are compared to cisplatin and…
- Trial name
- NCT02151084
- Testing
- Selumetinib, Cisplatin, Gemcitabine
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- University Health Network, Toronto
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.
- Trial name
- NCT03772132
- Testing
- mutation and signal pathway activation status analysis Drug: FORFIRINOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cholangiocarcinoma, Gallbladder Cancer
Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
To determine the activity of gemcitabine combined with carboplatin in the treatment of patients with metastatic or recurrent cholangiocarcinoma or gallbladder cancer.
- Trial name
- NCT00660140
- Testing
- Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Anal Cancer, Colorectal Cancer
Interleukin-12 in Treating Patients With Cancer in the Abdomen
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00003046
- Testing
- Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center